

Clinical characteristics of anti-SAE antibodies in Chinese comparison with different patient cohorts

Scientific Reports

7, 188

DOI: [10.1038/s41598-017-00240-6](https://doi.org/10.1038/s41598-017-00240-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Diagnosis of dermatomyositis: Autoantibody profile and muscle pathology. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 302-312.	0.5	7
2	Dermatomyositis: Autoantibodies and Their Corresponding Phenotypes. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 254-266.	0.6	1
3	Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 992.	2.2	74
4	Clinical contribution of myositis-related antibodies detected by immunoblot to idiopathic inflammatory myositis: A one-year retrospective study. <i>Autoimmunity</i> , 2018, 51, 89-95.	1.2	16
5	Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. <i>Clinics in Dermatology</i> , 2018, 36, 508-524.	0.8	20
6	Advances in biomarkers for dermatomyositis. <i>Clinica Chimica Acta</i> , 2018, 482, 172-177.	0.5	9
7	Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies. <i>Current Rheumatology Reports</i> , 2018, 20, 28.	2.1	76
8	Bench to bedside review of myositis autoantibodies. <i>Clinical and Molecular Allergy</i> , 2018, 16, 5.	0.8	59
9	A tough one to swallow. <i>Practical Neurology</i> , 2018, 18, 250-254.	0.5	2
10	The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. <i>Clinical Rheumatology</i> , 2018, 37, 1573-1580.	1.0	10
11	Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1164-1172.	1.3	33
12	Clinical significance of myositis-specific autoantibodies. <i>Immunological Medicine</i> , 2018, 41, 103-112.	1.4	34
13	Diffuse erythema with "angel wings" sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis. <i>British Journal of Dermatology</i> , 2018, 179, 1414-1415.	1.4	24
14	Classification and management of adult inflammatory myopathies. <i>Lancet Neurology</i> , The, 2018, 17, 816-828.	4.9	267
15	Polymyositis and dermatomyositis " challenges in diagnosis and management. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100018.	2.0	44
16	The Role of Autoantibodies in Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatic Diseases</i> , 2019, 26, 165.	0.4	11
18	Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1582-1586.	0.9	11
19	Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review. <i>Clinical Rheumatology</i> , 2019, 38, 2189-2193.	1.0	15

#	ARTICLE	IF	CITATIONS
20	Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. <i>Journal of Immunology Research</i> , 2019, 2019, 1-15.	0.9	18
22	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 643-649.	2.0	32
23	Classification of idiopathic inflammatory myopathies: pathology perspectives. <i>Current Opinion in Neurology</i> , 2019, 32, 704-714.	1.8	61
24	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.3	148
25	Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 79-89.	1.3	14
26	The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2150.	1.0	41
27	Inflammatory Muscle Diseases. , 0, , .		1
28	Autoantibody Biomarkers in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1382.	1.8	22
29	Dermatomyositis: An Update on Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 339-353.	3.3	54
30	A rare form of dermatomyositis associated with muscle weakness and normal creatine kinase level. <i>BMJ Case Reports</i> , 2020, 13, e232260.	0.2	5
31	Myositis Antibodies and Interstitial Lung Disease. <i>journal of applied laboratory medicine</i> , The, 2022, 7, 240-258.	0.6	11
32	Immune and Inflammatory Myopathies. , 2021, , 321-345.		0
33	Comparing different approaches for operationalizing subjective cognitive decline: impact on syndromic and biomarker profiles. <i>Scientific Reports</i> , 2021, 11, 4356.	1.6	17
34	Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report. <i>Pediatric Rheumatology</i> , 2021, 19, 34.	0.9	9
35	Dermatomyositis autoantibodies: how can we maximize utility?. <i>Annals of Translational Medicine</i> , 2021, 9, 433-433.	0.7	20
36	A North American Cohort of Anti-SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. <i>ACR Open Rheumatology</i> , 2021, 3, 287-294.	0.9	28
37	Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 672008.	2.2	8
38	Dermatomiositis paraneoplásica anti-SAE positivo de comportamiento agresivo. <i>Piel</i> , 2021, 36, 495-497.	0.0	0

#	ARTICLE	IF	CITATIONS
39	InÂvitro diagnostics for the medical dermatologist. Part I: Autoimmune tests. Journal of the American Academy of Dermatology, 2021, 85, 287-298.	0.6	2
40	Role of Myositis Autoantibodies in Management and Prognosis. , 2020, , 175-180.		1
41	Ä°nflamatuar miyozitler: Ä°diyopatik mi? Ä°takÄ±ÄŸma mÄ±? Paraneoplastik mi?. Ege TÄ±p Dergisi, 0, , 51-57.	0.1	0
42	Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 219-240.	2.7	6
43	Anti-SAE1 Antibodies and Dermatomyositis: A Case Series of Three Patients. SKIN the Journal of Cutaneous Medicine, 2020, 4, 578-584.	0.1	2
44	Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with antiâ€small ubiquitinâ€like modifier activating enzyme antibody. International Journal of Dermatology, 2022, 61, .	0.5	1
45	A Case of Anti-SAE1 Dermatomyositis. Case Reports in Immunology, 2022, 2022, 1-4.	0.2	1
46	Update on Cutaneous Signs to Assist in the Diagnosis of Dermatomyositis. Current Rheumatology Reports, 2022, 24, 156-165.	2.1	5
47	Recent research on myositis-specific autoantibodies in juvenile dermatomyositis. Chinese Journal of Contemporary Pediatrics, 2021, 23, 1064-1068.	0.2	2
48	The Utility of Myositis Specific Antibodies in Clinical Practice. journal of applied laboratory medicine, The, 2022, 7, 1189-1201.	0.6	3
49	Autoantibodies: Pathogenic or epiphenomenon. Best Practice and Research in Clinical Rheumatology, 2022, , 101767.	1.4	5
50	Cessation of immunomodulatory medication use in dermatomyositis: a single center cohort study. Arthritis Care and Research, 0, , .	1.5	0
51	Update on dermatomyositis. Current Opinion in Neurology, 2022, 35, 611-621.	1.8	8
52	Biomarkers of disease activity in dermatomyositis. Current Opinion in Rheumatology, 2022, 34, 289-294.	2.0	4
53	Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature. Immunologic Research, 2023, 71, 112-120.	1.3	2
54	Pericardial effusion in idiopathic inflammatory myopathies: A cross-sectional study from Asia and review of the literature. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211457.	1.0	1
55	Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology, 2023, 62, 3932-3939.	0.9	5
56	Idiopathic Inflammatory Myopathies. , 2023, , 37-72.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------